Financial Statements

AC Immune SA (ACIU)

$2.96

-0.07 (-2.31%)

Balance Sheet Statement

All numbers are in thousands
Year XLSX
2023
XLSX
2022
XLSX
2021
XLSX
2020
XLSX
2019
Total assets 182,814185,938261,443238,740299,250
Total Current Assets 125,153128,094202,634231,767292,774
Cash and Short Term Investments 103,048122,586198,216225,893288,587
Cash and cash equivalents 78,49431,58682,216160,893193,587
Short Term Investments 24,55491,000116,00065,00095,000
Receivables 15,6688001,4031,9201,399
Inventory -0-1,403-1,920-1,399
Other Current Assets -4,7084,4185,8744,187
Total non-current Assets 57,66157,84458,8096,9736,476
Property, Plant & Equipment Net 6,8847,0678,0306,6396,172
Goodwill and Intangible Assets 50,41650,41650,416--
Goodwill 50,41650,41650,416--
Intangible Assets 50,41650,41650,416--
Long Term Investments 361361363334304
Other non-current Assets -361363--
Total liabilities 22,17116,94729,46423,26226,808
Total current liabilities 13,57611,48120,02614,01817,510
Payables 1,6799292,0032,184142
Short Term debt 6725485704431,094
Deferred revenue 1385877173064,477
Other Current Liabilities 11,0879,41716,73611,08511,797
Total non-current liabilities 8,5955,4669,4389,2449,298
Long Term debt 2,8252,2532,3401,7801,813
Other non-current Liabilities 5,7703,2137,0987,4647,485
Total shareholders equity 160,643168,991231,979215,478272,442
Common Stock 2,0891,7971,7941,5381,437
Retained earnings -316,197-264,015-200,942-132,850-75,521
Accumulated Other Comprehensive Income Loss -5110---
Other Stockholders Equity 474,802431,199431,127346,790346,526
Total debt 3,4972,8012,9102,2232,907
Total Investments 24,91591,361116,36365,00095,304
Net Debt -74,997-28,785-79,306-158,670-190,680

AC Immune SA income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes AC Immune SA FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.